Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
verfasst von:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
A number of minor errors were introduced in the online ahead-of-print version of this article, as summarized below. These errors are corrected in the published version.
Anzeige
On page 1, a company name was changed from using an ampersand to the word “and.” The correct company name uses an ampersand: OPEN Health Evidence & Access.
On page 1, in the Results section of the Abstract, a space was inserted between the negative symbol and 2.0 in “[−2.0 to 16.7].”
In the graphical abstract on page 2, “anti–tumor” was changed to “anti! tumor” and will be amended in the figure.
×
On page 5, in the first full paragraph in the left column, “[PASI]” will be inserted after “Psoriasis Area and Severity Index” to spell out at first mention.
Anzeige
On page 5 under the subhead Outcomes, “Psoriasis Area and Severity Index [PASI]” will be changed to just “PASI” as it will have already been spelled out at first mention.
In the figure legend (title) for Figure 1, the superscript “a” will be removed from the end of the legend. It will only remain in the footnote, describing “a” used in the figure.
In Table 1 on page 8, the column heading “Deucravacitinib POETYK PSO-LTE” should be centered over the last 2 columns, as it applies to both columns below it.
In the footnote for Table 1, the definition of PGA should be “Physician Global Assessment” not Physician’s.
In Table 2 on page 11, the column heading “Deucravacitinib Adjusted POETYK PSO-LTE” should be centered on 1 line over the last 4 columns, as it applies to all 4 columns below it.
In the footnote for Table 2, the definition of PGA should be “Physician Global Assessment” not Physician’s.
Under Disclosures, the following change has been made: “Sang Hee Park, Vardhaman Patel, and David Davidson are employees of and may own stock options in Bristol Myers Squibb” is changed to “Sang Hee Park and Vardhaman Patel are employees of and may own stock options in Bristol Myers Squibb. David Davidson was an employee of Bristol Myers Squibb at the time of this study.”
Under Open Access, the word “license” is spelled differently throughout the paragraph as either license or licence. This has been corrected to the same spelling throughout the paragraph.
Anzeige
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
verfasst von
April W. Armstrong Sang Hee Park Vardhaman Patel Malcolm Hogan Wei-Jhih Wang David Davidson Viktor Chirikov
Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.
In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
